Study on Placental Blood Flow in Fetal Growth Restriction Using Sulfur Hexafluoride for Patients Undergoing Medical Termination of Pregnancy

This clinical trial is focused on studying fetal growth restriction, a condition where a baby does not grow as expected in the womb. The study will use a special imaging technique called contrast-enhanced ultrasound (CES) to examine the blood flow in the placenta, which is the organ that provides nutrients and oxygen to the baby during pregnancy. The treatment involves using a contrast agent called sulfur hexafluoride, which is a type of gas that helps improve the images taken during the ultrasound.

The purpose of the study is to compare the placental blood flow in two groups of pregnant women: those with fetal growth restriction and those without. Participants will receive an injection of the contrast agent, and then an ultrasound will be performed to capture detailed images of the placenta. This will help researchers understand how blood flow differs between the two groups and may provide insights into the causes of fetal growth restriction.

The study will involve a series of ultrasound examinations and the collection of placental samples for further analysis. These samples will be used to study the presence of sulfur hexafluoride in the placenta and to examine the structure of the placenta under a microscope. The study aims to gather valuable information that could lead to better understanding and management of fetal growth restriction in the future.